Brief: Veru Reports Clinical Data From The Discontinued Artest Study Of Enobosarm

Veru

11/09/2023 12:24

Sept 11 (Reuters) - Veru Inc  VERU.O :
    * VERU REPORTS CLINICAL DATA FROM THE DISCONTINUED ARTEST
STUDY OF
ENOBOSARM, NOVEL SELECTIVE ANDROGEN RECEPTOR TARGETING AGONIST,
IN AR+ ER+ HER2- METASTATIC BREAST CANCER
    * VERU INC - ENOBOSARM WAS GENERALLY WELL TOLERATED WITH NO
MASCULINIZING ADVERSE EVENTS OR HEMATOCRIT INCREASES
    * VERU - ORR RATES OF 12.5% OBSERVED IN ENOBOSARM GROUP IN
HEAVILY
PRETREATED POPULATION VERSUS NO RESPONSES IN STANDARD OF CARE
ACTIVE CONTROL ARM

Source text for Eikon:  ID:nGNX8XS87p 
Further company coverage:  VERU.O 

 ((Reuters.Brief@thomsonreuters.com;))